摘要
目的探讨腰痹通胶囊治疗腰椎终板骨软骨炎的临床疗效。方法选择2012年3月至2014年6月医院收治的腰椎终板骨软骨炎患者140例,随机分为对照组和观察组,各70例。两组患者均服用萘普生缓释胶囊配合牵引治疗,观察组患者在此基础上加用腰痹通胶囊。两组患者均治疗4周,观察两组患者的临床疗效,治疗前、治疗第2周及治疗结束后的疼痛视觉模拟(VAS)评分及腰痛Oswestry功能障碍指数(ODI)评分情况,记录不良反应的发生情况。结果观察组总有效率为91.43%,明显高于对照组的81.43%(P<0.05);治疗2周及治疗后,两组患者的VAS评分及腰痛ODI评分均较治疗前明显改善(P<0.05),且观察组改善情况显著优于对照组(P<0.05);两组患者不良反应均较轻,发生率比较,差异无统计学意义(P>0.05)。结论腰痹通胶囊治疗腰椎终板骨软骨炎疗效显著,可有效改善患者的临床症状及VAS评分、腰痛ODI评分,且无明显不良反应,值得临床推广。
Objective To discuss the efficacy of Yaobitong Capsules for lumbar endplate osteochondritis. Methods 140 patients with lumbar endplate osteochondritis from March 2012 to June 2014 in the hospital were randomly divided into the control group and the observation group,70 cases in each group. All patients took naproxen sustained release capsules with traction treatment,and on this basis,the observation group was added with Yaobitong Capsules. The two groups were treated for 4 weeks. The clinical efficacy,the VAS pain scores at the 2nd week and at the end of treatment,the ODI scores of the two groups were observed,and the adverse reactions were recorded. Results The total effective rate of the observation group was 91. 43%,which was significantly higher than 81. 43% of the control group（ P〈0. 05）. The VAS scores and ODI scores after two weeks of treatment and the end of treatment were improved compared with before treatment,and the improvement of the observation group was significantly better than the control group（ P〈0. 05）. The adverse reactions were mild in the two groups,and the incidence rates had no statistically significant difference between the groups（ P〈0. 05）. Conclusion Yaobitong Capsules for treating lumbar endplate osteochondritis has significant clinical efficacy,can effectively improve the clinical symptoms and VAS pain scores as well as ODI scores,with no significant adverse reactions,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第10期24-26,共3页
China Pharmaceuticals
基金
河北省石家庄市科学研究与发展计划
项目编号:141462563
关键词
腰痹通胶囊
腰椎终板骨软骨炎
疼痛
临床疗效
Yaobitong Capsules
lumbar endplate osteochondritis
pain
clinical efficacy
